Entyvio for Ulcerative Colitis (UC)
Long-term remission with either IV infusions or the ENTYVIO Pen*
*Patients can switch to the ENTYVIO Pen after at least 2 IV doses
Patient Portrayal
In two clinical trials, ENTYVIO delivered results for adults with moderate to severe ulcerative colitis when other medicines had not worked well enough or could not be tolerated.
The first study evaluated response to ENTYVIO versus placebo at Week 6. The second study included adults who had a previous response to ENTYVIO at Week 6 and evaluated remission at Week 52.
Results with IV infusion were seen as early as 6 weeks
ENTYVIO helped
NEARLY TWICE
as many people achieve response
vs placebo
At 6 weeks of treatment, 47% of people on ENTYVIO infused intravenously achieved response* compared to 26% of people on placebo.
Long-term remission with IV infusion
ENTYVIO helped
MORE THAN TWICE
as many people achieve
remission at 1 year
vs placebo
42% of people on ENTYVIO infused intravenously achieved remission† at 1 year of treatment, compared to 16% of people on placebo.
*Response is a measure to determine improvement of the patient's UC symptoms and condition.
†Remission is a measure to determine when a patient with UC is experiencing few to no symptoms and an improvement in their condition.
In the ENTYVIO clinical studies, clinical response and remission was defined and measured by improvement in the Mayo score, an assessment tool that measures stool frequency, rectal bleeding, appearance of the mucosal lining of the colon, and physician assessment.
Results your doctor can see
For many people, ENTYVIO infused intravenously improved how their intestinal lining looked to their doctor.
- As early as Week 6, 41% of patients experienced improvement compared to 25% of people on placebo
- At 1 year, 52% of patients experienced improvement compared to 20% on placebo
IMPORTANT SAFETY INFORMATION
- Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients.
-
ENTYVIO may cause serious side effects, including:
- Infusion-related and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. You may need treatment if you have an allergic reaction. Tell your healthcare provider or get immediate medical help if you get any of these symptoms during or after an infusion of ENTYVIO: rash, itching, swelling of your lips, tongue, throat, or face, shortness of breath or trouble breathing, wheezing, dizziness, feeling hot, or palpitations (feeling like your heart is racing).
Please see additional Important Safety Information below.
Remission with the ENTYVIO Pen
THE ENTYVIO PEN
helped more than three times
as many people achieve remission
at 1 year vs placebo
A separate clinical study evaluated remission at Week 52 in adult patients with moderate to severe UC who were administered ENTYVIO subcutaneously vs placebo.
46% of people administered ENTYVIO subcutaneously achieved remission at 1 year of treatment compared to 14% of people on placebo.
In a separate head-to-head study,
Humira is a registered trademark of AbbVie, Inc. For information related to adalimumab, please see AbbVie.com.
ENTYVIO helped
SIGNIFICANTLY MORE
adult patients with moderate to severe UC than HUMIRA® achieve remission at 1 year
31% of people on ENTYVIO given as IV infusion achieved remission at 1 year compared to 23% of people on HUMIRA.
Ask your doctor if ENTYVIO is right for you.
Sign up for EntyvioConnect
Ready to access everything EntyvioConnect has to offer? Sign up today!
Sign up
